Expert Pitch
University at Buffalo

Finance expert answers key questions during coronavirus pandemic

3-Apr-2020 2:10 PM EDT, by University at Buffalo

BUFFALO, N.Y. — As the COVID-19 crisis sweeps much of the world, people are worried not only about their health, but also about their jobs, their portfolios and their future.

And while stock prices and markets are not necessarily at the top of the list, an expert from the University at Buffalo School of Management offers some advice.

Cristian Tiu, PhD, associate professor and chair of the Department of Finance, specializes in stock markets, risk management and asset allocation. Below, he answers some of the top questions investors and families are asking now.

  1. Should I sell my portfolio and get out of the market right now?

    No. In fact, if you’re thinking opportunistically, you might buy some stocks if you can afford to. Amazon and Walmart have to continue to deliver. Everyone is moving to online teaching for a while, and Cisco, Zoom, Amazon and Microsoft are facilitators. Some airlines will rebound after being pounded severely from the beginning of this crisis.

    More generally, fixed-weight portfolios are rebalancing to their fixed weights by buying stocks right now, because the equity portion of those portfolios amounts to a lower-than-target percentage. Look for good dividend yields and bargains. Don’t sell low to buy high. 
  2. How can I protect myself financially? This is not an unusual question for America, a country thriving through individualism. Unfortunately, this is one instance in which individualism won’t pay off — for once, you should be thinking about your part in the solution.

    Keep your distance, avoid unnecessary outings, let a nurse in the grocery line go ahead of you. If everyone does these things, it can slow the spread of the virus, the crisis will be over sooner and we can return to our lives before this crisis. Be part of the solution, and you will be rewarded financially, too, in the economic recovery.
  3. Aren’t markets overreacting? Isn’t the flu worse?

    Mortality is worse for COVID-19, and the virus is more infectious. While I agree that the markets are overreacting (as volatility seems really high), they are overreacting to something that is already bad. Similarly, in markets in which sentiment is so dominant, overreaction as well as under-reaction by some investors are likely to spread. So crashes seem large, and rallies unrealistically large too.  
  4. Should I buy put options to hedge?

    A put is an options contract that gives the owner the right, but not the obligation, to sell a certain amount of an underlying asset at a set price within a specific time. And the answer is no, you should not buy put options — at least not right now.

    There are two things that make put options expensive: one is low prices (and the prices are low now) and the other is market high volatility (the index of volatility, the VIX, is also at very high levels now — about 70% when “normal” levels are more like 20%).

    If anything, for those with nerves of steel, this is the time to sell put options. This is going long in the market when the market is low, and selling volatility when the volatility is high. Again — only if you have nerves of steel. When it comes to stock prices, uncertainty brings volatility.
  5. What is a worst-case scenario and a best-case scenario for the U.S. economy?

    A worst-case scenario is one in which the economy stops for a longer time, and we see a deep recession. Consequently, supply will also be low, and thus prices will be high. That translates into economic contraction (think stock prices going down) coupled with inflation (value of money going down, too). This is the no-escape scenario of stagflation.

    Best-case scenario? We find antiviral drugs to slow the coronavirus down and produce a vaccine in record time. Moreover, we learn how to do this relatively quickly for any virus. As a result, confidence will increase and, happy we escaped, we will return to enjoying life by going out and traveling with the confidence that modern medicine can now efficiently fight viruses — something we are not very successful at currently.

Additional UB faculty experts who can provide insight on COVID-19 and its societal effects: 

The UB School of Management is recognized for its emphasis on real-world learning, community and economic impact, and the global perspective of its faculty, students and alumni. The school also has been ranked by Bloomberg Businessweek, Forbes and U.S. News & World Report for the quality of its programs and the return on investment it provides its graduates. For more information about the UB School of Management, visit

Filters close

Showing results

110 of 2539
Released: 13-Jul-2020 4:05 PM EDT
OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available
Organization for Associate Degree Nursing (OADN)

OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 3:05 PM EDT
Asymptomatic Transmission and Reinfection of COVID: Live Event for July 16, 2PM EDT

Emerging data shows more risk of asymptomatic transmission and reinfection with COVID than previously thought. Experts will discuss these findings and what are the implications for managing the pandemic. Media are invited to attend and ask questions.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.

Showing results

110 of 2539